JP2014530802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530802A5 JP2014530802A5 JP2014518853A JP2014518853A JP2014530802A5 JP 2014530802 A5 JP2014530802 A5 JP 2014530802A5 JP 2014518853 A JP2014518853 A JP 2014518853A JP 2014518853 A JP2014518853 A JP 2014518853A JP 2014530802 A5 JP2014530802 A5 JP 2014530802A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- pioglitazone
- release preparation
- preparation according
- polyethylene oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 76
- 239000003405 delayed action preparation Substances 0.000 claims description 52
- 229960005095 pioglitazone Drugs 0.000 claims description 38
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000000748 compression moulding Methods 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 229950008138 carmellose Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000007922 dissolution test Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 | ||
| JP2011232302 | 2011-10-21 | ||
| PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530802A JP2014530802A (ja) | 2014-11-20 |
| JP2014530802A5 true JP2014530802A5 (enExample) | 2015-11-26 |
| JP6093762B2 JP6093762B2 (ja) | 2017-03-08 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518853A Expired - Fee Related JP6093762B2 (ja) | 2011-10-21 | 2012-10-19 | 徐放性製剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9907789B2 (enExample) |
| EP (1) | EP2768487B1 (enExample) |
| JP (1) | JP6093762B2 (enExample) |
| KR (1) | KR20140081826A (enExample) |
| CN (1) | CN104039313A (enExample) |
| AP (1) | AP2014007645A0 (enExample) |
| AR (1) | AR088398A1 (enExample) |
| AU (1) | AU2012326976B2 (enExample) |
| BR (1) | BR112014008744A2 (enExample) |
| CA (1) | CA2852417A1 (enExample) |
| CL (1) | CL2014000992A1 (enExample) |
| CO (1) | CO6960544A2 (enExample) |
| CR (1) | CR20140213A (enExample) |
| DO (1) | DOP2014000077A (enExample) |
| EA (1) | EA201490840A1 (enExample) |
| EC (1) | ECSP14013328A (enExample) |
| IL (1) | IL232114A0 (enExample) |
| IN (1) | IN2014DN03169A (enExample) |
| MA (1) | MA35717B1 (enExample) |
| MX (1) | MX2014004679A (enExample) |
| NZ (1) | NZ624275A (enExample) |
| PE (1) | PE20141189A1 (enExample) |
| PH (1) | PH12014500856A1 (enExample) |
| SG (2) | SG10201700121YA (enExample) |
| TN (1) | TN2014000152A1 (enExample) |
| TW (1) | TW201323018A (enExample) |
| UA (1) | UA113858C2 (enExample) |
| UY (1) | UY34403A (enExample) |
| WO (1) | WO2013058409A1 (enExample) |
| ZA (1) | ZA201403103B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| EP0661045B1 (en) | 1992-09-18 | 2002-07-03 | Yamanouchi Pharmaceutical Co. Ltd. | Sustained-release hydrogel preparation |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
| KR20050053677A (ko) | 2002-09-20 | 2005-06-08 | 안드렉스 랩스 엘엘씨 | 비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태 |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| IN192749B (enExample) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| US8980322B2 (en) | 2003-03-17 | 2015-03-17 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| BRPI0410555A (pt) | 2003-06-06 | 2006-06-20 | Takeda Pharmaceutical | preparação sólida |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| WO2005099760A1 (ja) | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| BRPI0514416A (pt) | 2004-08-31 | 2008-06-10 | Pfizer Prod Inc | formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade |
| KR20080058413A (ko) | 2005-09-22 | 2008-06-25 | 에스비 팜코 푸에르토 리코 인크. | Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제 |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| RU2426530C2 (ru) | 2005-12-22 | 2011-08-20 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат |
| KR101455741B1 (ko) | 2006-03-30 | 2014-10-28 | 니폰 조키 세야쿠 가부시키가이샤 | 고형 의약 제제 |
| JP2009534292A (ja) | 2006-04-27 | 2009-09-24 | 武田薬品工業株式会社 | 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物 |
| AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| US8445190B2 (en) | 2008-09-30 | 2013-05-21 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| EP3106165B1 (en) | 2011-01-10 | 2019-02-27 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530802A5 (enExample) | ||
| JP7471675B2 (ja) | 多孔性シリカ粒子組成物 | |
| JP5937068B2 (ja) | 転用防止微粒剤および微小錠剤 | |
| JP5357032B2 (ja) | 誤用抵抗性製剤 | |
| AU2013356872B2 (en) | Oral form, comprising immediate-release coated particles of at least one active compound that are grinding-resistant | |
| KR101940840B1 (ko) | 디아민 유도체 함유 의약 조성물 | |
| JP2009526021A5 (enExample) | ||
| MX2010008711A (es) | Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada. | |
| TW201827049A (zh) | 含二胺衍生物之口腔崩散錠 | |
| JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| JPWO2010038688A1 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| EP2540318A1 (en) | Sustained-release solid preparation for oral use | |
| EP2994108B1 (en) | Oral pharmaceutical formulation | |
| CN102178657B (zh) | 一种奥氮平口腔崩解片 | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| UA82268C2 (uk) | Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення | |
| HK1208130A1 (en) | Extended-release levetiracetam and method of preparation | |
| JP2013237651A (ja) | ピタバスタチンの口腔内崩壊錠 | |
| JP2012140335A (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| JP5566757B2 (ja) | 固形製剤 | |
| JP2013023463A (ja) | 生理活性物質含有粒子の製造方法 | |
| JP2002012540A (ja) | 水易溶性薬物含有錠剤 | |
| JP6476122B2 (ja) | 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤 | |
| WO2019098327A1 (ja) | 速溶性薬物の苦味が抑制された口腔内崩壊錠 | |
| JP5764811B2 (ja) | 固形製剤 |